Overview

Webcast ImageWebcast
Q2 2017 Clovis Oncology, Inc. Earnings Conference Call (Live)
08/02/17 at 4:30 p.m. ET
Q2 2017 Clovis Oncology, Inc. Earnings Conference Call
Wednesday, August 2, 2017 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Clovis’ development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from their use. Clovis believes this approach to precision medicine – to deliver the right drMore >>

Stock Chart
Stock chart for: 03NA000000CLVS
Stock Quote
CLVS (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$86.64
Change (%) Stock is Up 1.37 (1.61%)
Intraday High$89.05
Intraday Low$85.03
Volume1,137,156
Data as of 07/21/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle  
07/19/17Clovis Oncology to Announce Second Quarter 2017 Financial Results and Host Webcast Conference Call on August 2
BOULDER, Colo.--(BUSINESS WIRE)--Jul. 19, 2017-- Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2017 financial results on Wednesday, August 2, 2017, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the company’s results in greater detail. The conference call is being webcast and can be accessed from the Clovis ... 
Printer Friendly VersionDownload PDF
06/21/17Clovis Oncology Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock
BOULDER, Colo.--(BUSINESS WIRE)--Jun. 21, 2017-- Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the underwriters of its recently announced public offering of its common stock have exercised in full their option to purchase an additional 511,363 shares. The offering, including the sale of the additional shares, is expected to close on June 26, 2017, subject to customary closing conditions. Clovis Oncology intends to use th... 
Printer Friendly VersionDownload PDF
06/20/17Clovis Oncology Announces Upsizing and Pricing of Public Offering of Common Stock
BOULDER, Colo.--(BUSINESS WIRE)--Jun. 20, 2017-- Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the pricing of an underwritten public offering of 3,409,091 shares of its common stock at $88.00 per share, before underwriting discounts and commissions. The size of the offering was upsized from $250 million to $300 million. In addition, the underwriters have a 30-day option to purchase up to an additional 511,363 shares of common stock from Clovis Onco... 
Printer Friendly VersionDownload PDF
Upcoming EventsMore >>
DateTitle
08/02/17
4:30 p.m. ET
Q2 2017 Clovis Oncology, Inc. Earnings Conference Call
Receive Email AlertsEmail Alert Icon
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.